NVS Fair Value Estimate
$194.5332.7% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Novartis AG
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Did you know?
Profit margin of 23.9% — that's well above average.
Current Price
$146.57
-0.87%GoodMoat Value
$194.53
32.7% undervaluedProfile
Valuation (TTM)
Market Cap$279.68B
P/E20.66
EV—
P/B6.06
Shares Out1.91B
P/Sales4.94
Revenue$56.58B
EV/EBITDA11.41
Novartis AG (NVS) Valuation
NVS Valuation Metrics
FCF$17.61B
FCF Growth Rate5.05%
EPS Growth (CAGR)2.97%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →NVS Valuation & Fair Value Analysis
Novartis AG (NVS) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Novartis AG is $194.53. The current stock price is $146.57, suggesting the stock is 32.7% undervalued.
The price-to-earnings (P/E) ratio is 20.66. Price-to-book ratio is 6.06. Price-to-sales ratio is 4.94. Enterprise value to EBITDA is 11.41. PEG ratio is -2.10.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Novartis AG's intrinsic value.